# Electromed, Inc. (ELMD) · Edgar & Edgarette company card

> Electromed (ELMD) grew revenue 15.3% in FY2026 to $74 million, operating margin 18.8% against a 7.5% median for electromedical & electrotherapeutic apparatus, equity 81.5% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1488917 · fiscal year ended 2026-06-30 · 5 audited years read · [page](https://www.pops4.com/boards/company/ELMD) · [JSON](https://www.pops4.com/boards/company/ELMD.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $74M |
| Revenue growth, 1 year | 15.3% |
| Revenue growth per year | 15.4% |
| Operating margin | 18.8% (prior year 15.1%) |
| Net margin | 15.3% |
| Operating cash flow | $10M |
| Capital spending | $1M |
| Free cash flow | $8M |
| Cash | $20M |
| Long-term debt | — |
| Total assets | $66M |
| Total equity | $54M |
| Equity ÷ assets | 81.5% |
| Return on equity | 20.9% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: 11.89 (safe zone)
- Piotroski F: 7 of 9 (solid)
- Beneish M: -2.23 (below the −1.78 line)
- Health Harbor boat: New ship · no warning signs
- Cash Compass: Cash cow later · growing fast, and already turning revenue into cash

## Edgarette's reading

Exposure: revenue $73.8M (FY2026). Experience: revenue up 15.3% on the year, up 15.4% a year over 4 years; operating margin 18.8%, up from 15.1%. Soundness: equity 81.5% of assets, return on equity 20.9%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $64.3M and $106.2M next year (method v4.1: its own 6-year record of growth weighed at 63% against $50M–100M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $65.5M to $104.4M. A statistical range, not company guidance. Against peers (13 filers, $50M+ revenue, electromedical & electrotherapeutic apparatus): operating margin 18.8% against a 7.5% median; growth 15.3% against 8.3%.

Range logged 2026-09-30, receipt eba81236e5d91bce, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 1, latest 2026-08-25 ([filing](https://www.sec.gov/Archives/edgar/data/1488917/000143774926028915/0001437749-26-028915-index.htm))

## Recent filings

- 10-Q · filed 2026-11-10 · [filing](https://www.sec.gov/Archives/edgar/data/1488917/000143774926036166/0001437749-26-036166-index.htm)
- 8-K · filed 2026-11-10 · 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1488917/000143774926036160/0001437749-26-036160-index.htm)
- DEF 14A · filed 2026-09-29 · [filing](https://www.sec.gov/Archives/edgar/data/1488917/000143774926031465/0001437749-26-031465-index.htm)
- 8-K · filed 2026-08-25 · 2.02 Results of Operations and Financial Condition; 5.02 Departure or Election of Directors; Appointment of Officers; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1488917/000143774926028915/0001437749-26-028915-index.htm)
- 10-K · filed 2026-08-25 · [filing](https://www.sec.gov/Archives/edgar/data/1488917/000143774926028914/0001437749-26-028914-index.htm)
- 10-Q · filed 2026-05-12 · [filing](https://www.sec.gov/Archives/edgar/data/1488917/000143774926016429/0001437749-26-016429-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001488917.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1488917

## Cite

POPS4, Edgar & Edgarette: Electromed, Inc. (ELMD) company card, from the company's own SEC filings, accessed 2026-11-14, https://www.pops4.com/boards/company/ELMD. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.